OptimizeRx (NASDAQ:OPRX) Downgraded to Buy Rating by Wall Street Zen

Wall Street Zen cut shares of OptimizeRx (NASDAQ:OPRX) from a strong-buy rating to a buy rating in a research note released on Saturday morning.

OPRX has been the topic of a number of other reports. Lake Street Capital dropped their price objective on shares of OptimizeRx from $20.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday. Zacks Research lowered shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, May 4th. Stifel Nicolaus dropped their price objective on shares of OptimizeRx from $17.00 to $14.00 and set a “buy” rating on the stock in a report on Wednesday. UBS Group set a $10.00 price objective on shares of OptimizeRx in a report on Wednesday. Finally, B. Riley Financial dropped their price objective on shares of OptimizeRx from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $13.43.

OptimizeRx Stock Performance

Shares of OPRX stock opened at $5.21 on Friday. The business’s fifty day simple moving average is $6.44 and its 200-day simple moving average is $10.68. The company has a market cap of $97.74 million, a PE ratio of 14.89 and a beta of 1.19. The company has a current ratio of 5.37, a quick ratio of 3.04 and a debt-to-equity ratio of 0.16. OptimizeRx has a 12-month low of $4.57 and a 12-month high of $22.25.

OptimizeRx (NASDAQ:OPRX) last announced its quarterly earnings data on Tuesday, May 12th. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.01 by $0.13. The firm had revenue of $19.84 million for the quarter, compared to analyst estimates of $18.74 million. OptimizeRx had a net margin of 6.37% and a return on equity of 10.86%. Analysts expect that OptimizeRx will post 0.5 earnings per share for the current fiscal year.

OptimizeRx announced that its board has approved a stock repurchase plan on Thursday, March 5th that allows the company to repurchase $10.00 million in outstanding shares. This repurchase authorization allows the company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its shares are undervalued.

Institutional Investors Weigh In On OptimizeRx

Several hedge funds have recently added to or reduced their stakes in the business. Hillsdale Investment Management Inc. boosted its holdings in OptimizeRx by 10.9% in the fourth quarter. Hillsdale Investment Management Inc. now owns 20,300 shares of the company’s stock valued at $249,000 after purchasing an additional 2,000 shares during the last quarter. Parkman Healthcare Partners LLC boosted its holdings in OptimizeRx by 0.4% in the third quarter. Parkman Healthcare Partners LLC now owns 509,611 shares of the company’s stock valued at $10,447,000 after purchasing an additional 2,188 shares during the last quarter. BNP Paribas Financial Markets boosted its holdings in OptimizeRx by 119.2% in the second quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock valued at $55,000 after purchasing an additional 2,215 shares during the last quarter. AQR Capital Management LLC boosted its holdings in OptimizeRx by 18.4% in the fourth quarter. AQR Capital Management LLC now owns 14,514 shares of the company’s stock valued at $178,000 after purchasing an additional 2,256 shares during the last quarter. Finally, Harbor Capital Advisors Inc. boosted its holdings in OptimizeRx by 12.2% in the fourth quarter. Harbor Capital Advisors Inc. now owns 24,876 shares of the company’s stock valued at $305,000 after purchasing an additional 2,708 shares during the last quarter. 76.47% of the stock is owned by hedge funds and other institutional investors.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.